Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5245MR)

This product GTTS-WQ5245MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5245MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10721MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ1187MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ598MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ5830MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ14723MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ3566MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ9076MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ2270MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.